Patient P-02118
Synthetic patientMETA-24 · Day 144 · 35–44 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
80%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 66 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 75 Patient accepted — Started GI-04 in the companion
- Day 83 GI symptom burden −19% vs expected — GI Support Protocol GI-04
- Day 86 ME-01 recommended — Monitoring Escalation ME-01
- Day 87 Patient accepted — Started ME-01 in the companion
- Day 89 Tolerance state changed — Unstable → Improving
- Day 90 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 66.
Primary contributors, last 14 days
- Inflammatory activity+8
- GI instability+7
- Nutritional resilience-4
- Treatment adherence-4
- Toxicity+3
What helped?
- GI Support Protocol GI-04Day 74Result: symptom burden −19%
- Monitoring Escalation ME-01Day 86Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
60%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable53 min
stable · +1.4 vs previous 14 d
Sleep duration
Wearable5.7 h
stable · +0.2 vs previous 14 d
Energy level
Daily log2.7/10
improving · +0.3 vs previous 14 d
Steps
Wearable6,603
stable · +104 vs previous 14 d
GI burden
Companion59.3/100
stable · +0.4 vs previous 14 d
Adherence
Companion44.4 %
improving · +2.7 vs previous 14 d
Sleep quality
Wearable21.4/100
improving · +5.4 vs previous 14 d
Glucose, CGM daily mean
CGM150 mg/dL
stable · +1.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 26 from the failing basin, 64 from restoration.
Would help
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 70%
- SC-12 Supportive Compound69% improved among 26 similar · onset 6 d · confidence 70%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 70%
- More proteinGI -4.7 next day on high-intake days · n 19
Would not help
- Keep histamine lowGI +4.5 next day on high-intake days · n 23
- Keep fat lowGI +4.2 next day on high-intake days · n 22
- Keep caffeine lowGI +3.8 next day on high-intake days · n 27
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.7supporter · 95%
- Histamine load+4.5detractor · 95%
- Dietary fat load+4.2detractor · 95%
- Caffeine+3.8detractor · 95%
- Insoluble fibre+1.5no signal · 43%
- Alcohol+0.9no signal · 23%
- Simple carbohydrates+0.5no signal · 15%
- Ultra-processed food-0.4no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- WearableSleep 5.7 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 24/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 46
- Autonomic recovery ↓45
- WearableResting HR 78 bpm
- WearableShort sleep window
- Inflammatory signalling ↑40
- BloodInflammatory load index 60
- WearableHRV 24 ms, trending down
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 24/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 26 ms
- Sleep
- 6.6 h
- Steps
- 6,486
- Resting HR
- 77 bpm
Daily log: GI score 59, nutritional resilience 42, adherence 44.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02363 | 58% | S14 | GI-04 | improved | 49 |
| P-02574 | 55% | S14 | ME-01 | improved | 45 |
| P-02348 | 54% | S14 | GI-04 | improved | 49 |
| P-02643 | 53% | S14 | SC-12 | improved | 46 |
| P-02132 | 52% | S14 | SC-12 | improved | 40 |
| P-02244 | 52% | S14 | GI-04 | improved | 46 |
| P-02320 | 51% | S14 | NP-02 | improved | 50 |
| P-02633 | 51% | S14 | NP-02 | improved | 48 |
| P-02648 | 51% | S14 | SC-12 | improved | 47 |
| P-02268 | 49% | S14 | GI-04 | improved | 43 |
| P-02505 | 49% | S14 | NP-02 | improved | 45 |
| P-02670 | 49% | S14 | SC-12 | improved | 45 |